
There are numerous criteria to be met by label manufacturers. In this context, topics such as patient compliance and smart …

Vertex Pharmaceuticals announced the appointment of J&J veteran, Tom Graney, as Senior Vice President and Chief Financial Officer. Graney will …

Leukaemia is a household name, but how much do we really understand about it? Not enough, says Bethany Torr, Campaigns …

Scientists at the Baylor College of Medicine, University of Texas have developed a device which they claim can identify cancerous …

The FDA has placed a partial hold on clinical trials involving Bristol-Myers Squibb’s immunotherapy treatment, Opdivo, when used in combination …

An anti-TSLP monoclonal antibody jointly developed by Amgen and AstraZeneca’s global biologics and research division, MedImmune, has met its primary …

MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …

AstraZeneca has revealed new data supporting the long-term use and efficacy of its cardiovascular drug Brilinta (ticagrelor), showing that the …

French clinical-stage biopharma firm Cellectis has received an order from the FDA to halt its study of CAR T therapy …

Novo Nordisk has resolved a probe by the US Justice Department which accused the Danish drugmaker of illegal marketing activities …

A new study has found that pre-exposure prophylaxis (PrEP) drugs such as Gilead’s Truvada (emtricitabine/tenofovir disoproxil fumarate), which pre-emptively protects …

Bial and Eisai have released real-world data which support the efficacy of Zebinix (eslicarbazepine acetate) in the treatment of partial-onset …

Novartis has announced that its Chief Executive, Joe Jimenez, is set to retire next year. In his place, Vasant Narasimhan …

NICE has revealed that the outcome of its consultation process for Ninlaro (ixazomib), Takeda’s treatment for relapsed or refractory multiple …

Merck KGaA has revealed plans to continue its commitment to a key partnership with the Ugandan Government via its non-profit …

Back in 2000, Pfizer had a drug that was granted accelerated approval for the treatment of acute myeloid leukaemia (AML) …

Novartis has announced results of its Phase 3 study investigating the safety and efficacy of Gilenya (fingolimod) , finding that …

Merck KGaA has revealed that it is looking to sell its consumer healthcare business, in order to refocus the business …

A study from the Department of Global Public Health and Primary Care at the University of Bergen (UiB) in Norway …

New findings from Public Health England (PHE)’s Heart Age Test indicate that around 10% of men in the UK are …